Hunan Fangsheng Pharm Co Ltd

Fangsheng Pharmaceutical released its 2026 interim report. Total operating revenue was 958 million yuan, net profit attributable to the parent company was 198 million yuan, and net cash inflow from operating activities was 270 million yuan. The company's latest asset-liability ratio was 39.57%, gross margin was 75.81%, return on equity was 11.12%, and diluted earnings per share was 0.45 yuan. Total asset turnover was 0.31 times, and inventory turnover was 0.67 times. The number of shareholders was 23,700, and the top ten shareholders held 46.76% of the total share capital.

Fangsheng Pharmaceutical released its 2026 interim report. In the first half, net profit attributable to the parent rose 16.8% year on year to 198 million yuan, while operating revenue grew 14.8% to 958 million yuan. In the second quarter, operating revenue increased 18.9% year on year to 495 million yuan, and net profit attributable to the parent climbed 34.9% to 109 million yuan. As of the end of the second quarter, total assets stood at 3.092 billion yuan, up 1.2% from the end of the previous year, and net assets attributable to the parent reached 1.777 billion yuan, up 3.8%. The company said its main business has not undergone major changes, and it remains focused on pharmaceutical research and development, production and sales, with products covering cardiovascular and cerebrovascular, musculoskeletal, and pediatric medicines. Through refined management and cost reduction and efficiency improvement, it achieved growth in both revenue and net profit.

Fangsheng Pharmaceutical announced that its Patch Workshop 1, Patch Production Line 1, has passed the GMP compliance inspection by the Hunan Medical Products Administration. The production line has a designed capacity of 72 million patches per year, primarily producing loxoprofen sodium gel patches. Previously, subsidiary Guangdong Fangsheng Jianmeng Pharmaceutical had obtained the Drug Registration Certificate for this product.

Fangsheng Pharmaceutical recently completed the change registration for its Drug Manufacturing License and obtained a new certificate issued by the Hunan Medical Products Administration. The main change involves adding cream products, for registration filing only, to the production scope at the manufacturing site at 789 Lushong Road, Changsha, while the scope for adhesive plasters, previously for registration filing only, has been changed to adhesive plasters. The license is valid until October 16, 2030, with Zhou Xiaoli serving as both legal representative and responsible person.